New drug cocktail shows promise for CLL patients
Disease control
Ongoing
This study tests a combination of three drugs (acalabrutinib, umbralisib, and ublituximab) in people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma. The goal is to see how many patients achieve complete remission after 24 cycles of treatment. The study incl…
Phase: PHASE2 • Sponsor: Jennifer R. Brown, MD, PhD • Aim: Disease control
Last updated May 14, 2026 12:02 UTC